Skip to Content

Posts tagged with "Drug Industry History"

  • Business and Markets

    Pfizer Versus BMS, Since 1989

    I very much enjoyed this piece by Bernard Munos on Pfizer. It follows the same method as this classic article by Matthew Herper (updated here, commented on here and here): If you want to figure out how much a company is spending per new drug, take a reasonably long period, add up all the R&D… Read More
  • Business and Markets

    Pfizer: One Step Ahead of the Mudslide

    Mentioning Pfizer/Allergan prompts me to strongly recommend this post by Bernard Munos: “Pfizer Does Not Need a Merger – It Needs a Rebellion”. He takes the long view, and the long view here is not pretty. Over the last ten or fifteen years, you’d have been better owning the S&P than Pfizer (and yes, that… Read More
  • Drug Development

    The Economist’s Take On Drug Discovery

    The Economist has one of those articles that makes a person wonder. It’s a long-remarked phenomenon that whenever a newspaper writes about something that you really know, the omissions and inaccuracies that show up should make you uneasy about their coverage of everything else. And so it is here, unfortunately. The hook for the piece… Read More
  • Chemical News

    Boring! Or: The Medicinal Chemist’s Toolkit

    There’s a new paper out on a topic that is of great interest for medicinal chemists: what sort of chemistry is it that we’re spending all our time doing? It’s a study of the literature from 1984 to 2014, analyzed by reaction type and other factors, and here’s the take-home: “. . .of the current… Read More
  • Drug Development

    Idiocy On Drug Research Costs

    Here’s a piece from the Center for Economic and Policy Research that claims to have the whole high-drug-price problem figured out. It’s “incredibly inefficient research”, just so you know. How does the CEPR know, you ask? They do a comparison of the costs of research (as provided by the Center for the Study of Drug Developm… Read More
  • Drug Industry History

    C-Nucleosides Never Went Away

    Here’s a paper in J. Med. Chem. calling for a revival of work in the C-nucleoside area. To some extent, these compounds never went away, but it’s certainly true that there was a period where many more groups were working on them. When I was looking for an undergraduate research project to do during my… Read More
  • Cancer

    A Biotech Education, In Progress

    Peter Thiel is worth paying some attention to. And it’s not just because he’s a wealthy venture capitalist – his views on pharma and biotech research are worth noting because he’s an excellent example of an intelligent, motivated outsider, someone with a strong technical background who’s approaching drug discovery de n… Read More
  • Drug Industry History

    That One Big Answer

    This post by Wavefunction on the foxes-and-hedgehogs split in drug discovery is well worth reading. You may recall, via Isaiah Berlin and Archilochus, that a fox knows many things, while a hedgehog knows one big thing. Here’s how that can apply to the drug R&D business: Now drug discovery should be the poster boy for… Read More
  • Cancer

    ABT-199 Nears Its Finish Line

    A couple of years back, AbbVie ran into an unusual problem in the clinic. Their Bcl ligand, ABT-199, was working a bit too well, and killing off so many leukemia cells that the resulting cellular debris was causing kidney trouble in some patients. The company immediately started working on clinical protocols to get things restarted… Read More
  • Alzheimer's Disease

    On the FDA, Drug Approvals, and Not Knowing Enough

    It doesn’t seem to have generated many headlines, but the FDA recently released a report (PDF) on the pace of drug development. Titled “Targeted Drug Development: Why Are Many Diseases Lagging Behind”, it seems to be motivated, at least in part, by a desire to answer “Not Because of Us!” The agency goes into some deta… Read More
...678...